Posted by Michael Wonder on 24 Feb 2021
NICE terminates appraisal of Novartis medicine
24 February 2021 - NICE had intended to appraise omalizumab for the treatment of patients with chronic rhinosinusitis with nasal polyps.
NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals did not provide an evidence submission.
